Literature DB >> 24724181

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

Stephen Salloway, Reisa Sperling, H Robert Brashear.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24724181     DOI： 10.1056/NEJMc1402193

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  27 in total

1.  D-Glucose uptake and clearance in the tauopathy Alzheimer's disease mouse brain detected by on-resonance variable delay multiple pulse MRI.

Authors:  Lin Chen; Zhiliang Wei; Kannie Wy Chan; Yuguo Li; Kapil Suchal; Sheng Bi; Jianpan Huang; Xiang Xu; Philip C Wong; Hanzhang Lu; Peter Cm van Zijl; Tong Li; Jiadi Xu
Journal:  J Cereb Blood Flow Metab       Date:  2020-07-16       Impact factor: 6.200

2.  Aβ vaccination in combination with behavioral enrichment in aged beagles: effects on cognition, Aβ, and microhemorrhages.

Authors:  Paulina R Davis; Ginevra Giannini; Karin Rudolph; Nathaniel Calloway; Christopher M Royer; Tina L Beckett; M Paul Murphy; Frederick Bresch; Dieter Pagani; Thomas Platt; Xiaohong Wang; Amy Skinner Donovan; Tiffany L Sudduth; Wenjie Lou; Erin Abner; Richard Kryscio; Donna M Wilcock; Edward G Barrett; Elizabeth Head
Journal:  Neurobiol Aging       Date:  2016-09-26       Impact factor: 4.673

3.  Transcranial optical imaging reveals a pathway for optimizing the delivery of immunotherapeutics to the brain.

Authors:  Benjamin A Plog; Humberto Mestre; Genaro E Olveda; Amanda M Sweeney; H Mark Kenney; Alexander Cove; Kosha Y Dholakia; Jeffrey Tithof; Thomas D Nevins; Iben Lundgaard; Ting Du; Douglas H Kelley; Maiken Nedergaard
Journal:  JCI Insight       Date:  2018-10-18

4.  The Future for Dementia Research: a Perspective from the Journal of Molecular Neuroscience.

Authors:  Illana Gozes
Journal:  J Mol Neurosci       Date:  2016-11       Impact factor: 3.444

5.  Combination of Aβ Suppression and Innate Immune Activation in the Brain Significantly Attenuates Amyloid Plaque Deposition.

Authors:  Christophe Verbeeck; Anna Carrano; Paramita Chakrabarty; Joanna L Jankowsky; Pritam Das
Journal:  Am J Pathol       Date:  2017-09-15       Impact factor: 4.307

6.  Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease.

Authors:  Zhicheng Chen; David Mengel; Ashvini Keshavan; Robert A Rissman; Andrew Billinton; Michael Perkinton; Jennifer Percival-Alwyn; Aaron Schultz; Michael Properzi; Keith Johnson; Dennis J Selkoe; Reisa A Sperling; Purvish Patel; Henrik Zetterberg; Douglas Galasko; Jonathan M Schott; Dominic M Walsh
Journal:  Alzheimers Dement       Date:  2018-11-09       Impact factor: 21.566

Review 7.  Efficacy of curcumin for age-associated cognitive decline: a narrative review of preclinical and clinical studies.

Authors:  Marjana Rahman Sarker; Susan F Franks
Journal:  Geroscience       Date:  2018-04-21       Impact factor: 7.713

8.  Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs.

Authors:  Holly Posner; Rosie Curiel; Chris Edgar; Suzanne Hendrix; Enchi Liu; David A Loewenstein; Glenn Morrison; Leslie Shinobu; Keith Wesnes; Philip D Harvey
Journal:  Innov Clin Neurosci       Date:  2017-02-01

Review 9.  Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain?

Authors:  Guillermo Moya-Alvarado; Noga Gershoni-Emek; Eran Perlson; Francisca C Bronfman
Journal:  Mol Cell Proteomics       Date:  2015-12-11       Impact factor: 5.911

10.  Blood-Brain Barrier Permeability in Aging and Alzheimer's Disease.

Authors:  G A Rosenberg
Journal:  J Prev Alzheimers Dis       Date:  2014-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.